This brand name is authorized in Turkey
The drug LITHOFALK contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Ursodeoxycholic acid
UNII 724L30Y2QR - URSODIOL
|
|
The ursodeoxycholic acid converts lithogenic bile in non-lithogenic bile and gradually dissolves the cholesterol gallstones. |
|
2
Chenodeoxycholic acid
UNII 0GEI24LG0J - CHENODIOL
|
|
Exogenous chenodeoxycholic acid is used as replacement therapy to restore the feedback inhibition lost due to the deficiency/absence of endogenous chenodeoxycholic acid. In CTX, deficiency of chenodeoxycholic acid causes a lack of feedback of cholesterol 7 alpha hydroxylase (CYP7A1) and HMG CoA reductase, causing increased production of atypical bile acids, bile alcohols and cholestanol that lead to the pathological consequences of the condition. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| A05AA | Bile acid preparations | A Alimentary tract and metabolism → A05 Bile and liver therapy → A05A Bile therapy |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: TR | ฤฐlaรง ve Tฤฑbbi Cihaz Kurumu | Identifier(s): 8699543090016 |
ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
